Mirikizumab: Primary completion of P3 LUCENT 2 trial (NCT03524092) in moderate-to-severe ulcerative colitis in Mar 2021 (Eli Lilly) - Jul 31, 2020 - Q2 2020 Results: Primary completion of P3 LUCENT-ACT trial (NCT04469062) for ulcerative colitis in Mar 2024; Completion of P3 LUCENT-ACT trial for ulcerative colitis in Jun 2024
Trial completion date • Trial primary completion date • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
|